Skip to content
OpenSampling

2025 · Frontiers in medicine · open access

The status quo of the development of decentralized clinical trials

Chen et al.

The finding, in our words

This literature review maps the regulatory landscape for decentralised clinical trials across the US, EU and China, finding that the US emphasises efficiency and technological integration, the EU prioritises equity and patient engagement, and China focuses on rare diseases with a cautious regulatory approach. It argues that fragmented governance across jurisdictions hampers the full realisation of DCTs and calls for greater international harmonisation.

A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.

Read the source ↗DOI 10.3389/fmed.2025.1664648PubMed 41346994

Labels

Papers that share these labels

  1. 2026

    The study identified 48 strengths, 62 weaknesses, 5 opportunities, and 13 threats across eight key trial activities in decentralised clinical trials, highlighting potential advantages like remote participation and challenges such as digital technology barriers and privacy issues.

    SWOT analysis of decentralised clinical trials from an ethical, legal, regulatory and operational perspective — Murciano-Gamborino et al., BMC medical ethics · source ↗

    • dct
    • standards

  2. 2025

    A critical assessment of recent decentralised trial experience, weighing what the model has delivered against what was claimed for it.

    Decentralized Clinical Trials in the Era of Real-World Evidence: A Critical Assessment of Recent Experiences — Wang et al., Clinical and Translational Science · source ↗

    • dct
    • standards
    • digital-biomarker

  3. 2025

    A recommendation paper on extending decentralised elements in trials, covering the conditions under which trial activity, including biological sample collection, may take place away from the investigator site.

    Recommendation Paper on Advancing the Use of Decentralised Elements in Clinical Trials — Bond et al., Therapeutic Innovation & Regulatory Science · source ↗

    • dct
    • standards

  4. 2025

    The Trials@Home RADIAL trial's regulatory record across six European countries: early and continuous engagement with regulators made the decentralised elements possible, and harmonised guidance is still needed where national legislation differs.

    Regulatory Interactions and Learnings-RADIAL the Trials@Home Proof-of-Concept Trial on Decentralization — Gardarsdottir et al., Clinical pharmacology and therapeutics · source ↗

    • dct
    • standards

  5. 2025

    The authors outline that FDA supports decentralised clinical trials to boost participation, noting that while they offer convenience for participants, successful implementation requires careful coordination, remote supervision, training, and risk management. This matters because it establishes the regulatory context and operational considerations for deploying patient-centric microsampling and remote monitoring in drug development.

    Decentralized Clinical Trials in the Development of Drugs and Biological Products — Robinson & Sacks, Therapeutic innovation & regulatory science · source ↗

    • dct
    • standards